



Mechanisms of viral mutation

Rafael Sanjuán¹ · Pilar Domingo-Calap^{2,3}

Received: 5 May 2016 / Revised: 20 June 2016 / Accepted: 22 June 2016 / Published online: 8 July 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract The remarkable capacity of some viruses to adapt to new hosts and environments is highly dependent on their ability to generate de novo diversity in a short period of time. Rates of spontaneous mutation vary amply among viruses. RNA viruses mutate faster than DNA viruses, single-stranded viruses mutate faster than double-strand virus, and genome size appears to correlate negatively with mutation rate. Viral mutation rates are modulated at different levels, including polymerase fidelity, sequence context, template secondary structure, cellular microenvironment, replication mechanisms, proofreading, and access to post-replicative repair. Additionally, massive numbers of mutations can be introduced by some virus-encoded diversity-generating elements, as well as by host-encoded cytidine/adenine deaminases. Our current knowledge of viral mutation rates indicates that viral genetic diversity is determined by multiple virus- and host-dependent processes, and that viral mutation rates can evolve in response to specific selective pressures.

Keywords Virus · Mutation rate · Replication fidelity · Hyper-mutation · Post-replicative repair · Genetic diversity · Evolution

Abbreviations

APOBEC	Apolipoprotein B mRNA-editing catalytic polypeptide-like enzymes
ADAR	dsRNA-dependent adenosine deaminase
AZT	Azidothymidine
CTL	Cytotoxic T lymphocyte
DDR	DNA damage response
HBV	Hepatitis B virus
HCV	Hepatitis C virus
MMR	Methyl-directed mismatch repair
PKR	Protein kinase R
ROS	Reactive oxygen species
SHAPE	Selective 2'-hydroxyl acylation analyzed by primer extension
UNG	Uracil DNA glycosylases

✉ Rafael Sanjuán
rafael.sanjuan@uv.es

¹ Department of Genetics and Institute for Integrative Systems Biology (I2SysBio), Universitat de València, C/Catedrático José Beltrán 2, 46980 Paterna, Valencia, Spain

² Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, LabEx Transplantex, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France

³ Fédération Hospitalo-Universitaire OMICARE, Centre de Recherche d'Immunologie et d'Hématologie, Strasbourg, France

Introduction

The mutation rate of an organism is defined as the probability that a change in genetic information is passed to the next generation. In viruses, a generation is often defined as a cell infection cycle, which includes attachment to the cell surface, entry, gene expression, replication, encapsidation, and release of infectious particles. Mutations are not restricted to replication since they can also result from editing of the genetic material, or spontaneous nucleic acid damage. The mutation rate should not be confused with the frequency at which mutations are found in a given viral population. The latter is a measure of genetic variation that

depends on a number of other processes such as natural selection, random genetic drift, recombination, and so on (Fig. 1a). Higher mutation rates lead to higher genetic diversity but, except in special cases, it is not possible to infer mutation rates directly from observed population mutation frequencies [1]. Although genetic diversity depends on multiple factors, the mutation rate is of particular interest because it constitutes the ultimate source of genetic variation. Similarly, mutation rates should not be confused with molecular evolutionary rates. The neutral theory of molecular evolution posits a linear relationship between these two rates, but whereas mutation is a biochemical/genetic process, molecular evolution refers to the fixation of new alleles in populations [2, 3].

Knowledge of the processes underlying viral mutation rates has implications for understanding and managing drug resistance, immune escape, vaccination, pathogenesis, and the emergence of new diseases. In clinics, the importance of viral mutation rates can be illustrated by the history of anti-HIV treatment. The nucleoside analog zidovudine (AZT) was the first approved anti-HIV drug but, unfortunately, the appearance of drug-resistant variants rapidly frustrated this monotherapy. HIV-1 is a fast-mutating virus and produces every possible single-base substitution (including AZT-resistance mutations) within a patient everyday [4]. The subsequent success of highly active antiretroviral therapy did not reside on merely increasing drug potency but mainly in combining different drugs (including AZT), such that the chances of resistance mutations appear were minimized. Qualitatively, the same argument holds for other rapidly mutating viruses such as hepatitis C virus (HCV). Multiple resistances have been already described against new HCV treatments [5], and analysis of population sequences has shown that resistance to protease inhibitors and non-nucleoside polymerase

inhibitors pre-exist naturally in treatment-naïve patients, that is, in the absence of selection favoring these mutations [6]. At present, combination therapies are the only effective treatment strategy for chronic diseases caused by fast-mutating viruses.

A similar scenario can be depicted for antiviral immunity. Viruses showing high mutation rates tend to evade immunity more efficiently. There are numerous examples of cytotoxic T lymphocyte (CTL) and antibody evasion in HIV-1, HCV, and hepatitis B virus (HBV), three fast-mutating viruses causing chronic infections. In HBV, the most common cause of hepatitis worldwide with nearly 350 million people chronically infected, a series of point mutations have been associated with immune escape and vaccination failure [7]. In acute viruses, immune escape takes place at the host population level instead of at the intra-host level. In this case, the benefit of escape resides in the ability of the virus to re-infect hosts that have developed protective immunity or infect hosts with that recognize the same antigens. The best-known example is influenza virus, which constantly undergoes antigenic changes and therefore requires yearly vaccine updates. Current efforts focus on developing influenza vaccines that target evolutionarily more conserved, yet sufficiently immunogenic protein domains [8]. Viral genetic diversity, which is ultimately determined by mutation rates, has therefore a profound effect on the design of antiviral strategies.

Viral mutation rates are not merely caused by polymerase errors, but also by the ability of a virus to correct DNA mismatches by proofreading and/or post-replicative repair. Furthermore, other sources of mutation include host enzymes, spontaneous nucleic acid damage, and even special genetic elements located within some viral genomes whose specific function is to produce new mutations




Fig. 1 Mutation rate definition. **a** Basic processes determining population genetic diversity. The observed population frequency of a mutation depends on the rate at which it is produced (mutation rate), but also on natural selection, random genetic drift, and recombination, among other processes. Most mutations are deleterious and tend to be removed from the population by selection, whereas beneficial mutations or combinations of mutations can be maintained/favored. Recombination can also contribute to the maintenance of genetic diversity. Random genetic drift leads to allele fixation and hence reduces population genetic diversity. **b** Basic processes determining

viral mutation rates. Mutations originate from replication errors, nucleic acid damage, and editing of the genetic material by host-encoded proteins or by specialized molecular systems such as diversity-generating retro-elements (DGRs). If these changes are not corrected, they will be passed to the viral progeny and hence will contribute to elevating the viral mutation rate. Expression of host error-prone polymerases may also contribute to creating new mutations in viruses. Recombination can also enhance the ability of some viruses to create new mutations by increasing gene copy number or by producing genome rearrangements

(Fig. 1b). Mutation rates are modulated by additional factors, including proteins involved in replication other than the polymerase, the mode of replication, and the template sequence and structure. In this review, we discuss how these different factors control viral mutation rates.

RNA viruses versus DNA viruses

The Baltimore classification of viruses establishes the following categories according to the genetic material contained in the virion: positive-strand RNA viruses (e.g., rhinoviruses, hepatitis C virus, noroviruses, tobacco mosaic virus), negative-strand RNA viruses (influenza viruses, Ebola virus, rabies virus), double-strand RNA viruses (rotaviruses, bursal disease virus), retroviruses (HIV, human T cell leukemia virus), para-retroviruses (hepatitis B viruses), single-stranded DNA viruses (parvoviruses, bacteriophage ϕ X174), and double-stranded DNA viruses (papillomaviruses, herpesviruses, adenoviruses, poxviruses). Viruses are the biological systems with the widest variation in mutation rates, the largest differences being found between RNA and DNA viruses. A summary of mutation rates for different viruses is provided in Table 1. As discussed in previous work, the reliability of some of these rates is compromised by several sources of estimation error and bias [1]. Despite these uncertainties, it can be inferred that viral mutation rates roughly range between 10^{-8} and 10^{-4} substitutions per nucleotide per cell infection (s/n/c), with DNA viruses occupying the 10^{-8} – 10^{-6} range and RNA viruses the 10^{-6} – 10^{-4} range (Fig. 2a). These differences have several mechanistic bases. First, the polymerases of the vast majority of RNA viruses lack 3' exonuclease proofreading activity and hence are more error-prone than those of DNA viruses [9, 10]. The exception to this rule is provided by coronaviruses, a family of positive-strand RNA viruses encoding a complex RNA-dependent RNA polymerase that has a 3' exonuclease domain [11]. Reverse transcriptases (RTs) also lack 3' exonuclease activity [12, 13] and, hence, retroviruses (viruses with RNA-containing virions and a cellular DNA stage) and para-retroviruses (viruses with DNA-containing virions and a cellular RNA stage) mutate and evolve at rates similar to those of non-reverse transcribing RNA viruses (the latter are often called riboviruses).

Whereas the dichotomy between RNA/RT and DNA viruses is well established from genetic and mechanistic standpoints, differences are less clear from the point of view of molecular evolution [14]. Some DNA viruses have been shown to evolve at rates close to those of RNA viruses, including emerging canine parvovirus strains [15], human parvovirus [16], tomato yellow leaf curl geminivirus [17], beak-and-feather disease circovirus [18], and

African swine fever virus (ASFV) [19], among others. This underscores the fact that evolution depends on multiple factors other than mutation rate, but also that mutation rates are unknown for many DNA viruses and may, in some cases, be higher than currently believed. Recent work with human cytomegalovirus has suggested a genome-wide average of 2×10^{-7} s/n/c, a value slightly higher than previously thought for a large double-strand DNA virus [20], although this estimate was indirect. Since many DNA and RNA viruses share similar lifestyles, the question arises as to why mutation rates should have evolved so differently in these two broad groups.

Single-strand viruses show higher mutation rates than double-strand viruses

Single-strand DNA viruses tend to mutate faster than double-strand DNA viruses, although this difference is based on work with bacteriophages, as no mutation rate estimates have been obtained for eukaryotic single-strand DNA viruses [1]. Within RNA viruses, there are no obvious differences in mutation rate among Baltimore classes (Fig. 2a). The mechanisms underlying these differences are not well understood. One possible explanation for the differences between single and double-strand viruses is that single-strand nucleic acids are more prone to oxidative deamination and other types of chemical damage. Elevated levels of reactive oxygen species (ROS) and other cellular metabolites during viral infections can induce mutations in the host cell and in the virus. For instance, ethanol is likely to synergize with virus-induced oxidative stress to increase the mutation rate of HCV [21]. Differences among single- and double-strand DNA viruses may also be explained in terms of their access to post-replicative repair. Work with bacteriophage ϕ X174 has provided interesting clues on this issue. In enterobacteria, methyl-directed mismatch repair (MMR) is performed by MutHLS proteins and Dam methylase. Dam methylation of GATC sequence motifs is used to differentiate the template and daughter DNA strands and is thus required to perform mismatch correction [22]. Mismatches are recognized by MutS, which interacts with MutL and leads to the activation of the MutH endonuclease, which excises the daughter strand. However, the genome of bacteriophage ϕ X174 has no GATC sequence motifs, even if approximately 20 such sites are expected by chance. As a result, the ϕ X174 DNA cannot undergo MMR. This contributes to explaining the relatively high mutation rate of this virus, which falls on the order of 10^{-6} s/n/c, a value three orders of magnitude above that of *Escherichia coli* and highest among DNA viruses [23]. Avoidance of GATC motifs may be a consequence of selection acting on mutation rate, but also of

Table 1 Summary of viral mutation rates

Class	Virus	Genome size (kb)	Average mutation rate (s/n/c) ^a	Individual estimates (s/n/c) ^b and references
ss(+)RNA	Bacteriophage Q β ^c	4.22	1.4×10^{-4}	1.4×10^{-4} [29]
	Tobacco mosaic virus	6.40	8.7×10^{-6}	8.7×10^{-6} [128]
	Human rhinovirus 14	7.13	6.9×10^{-5}	4.8×10^{-4} [129], 1.0×10^{-5} [130]
	Poliovirus 1	7.44	9.0×10^{-5}	2.2×10^{-5} [131, 132], 1.1×10^{-4} [133], 3.0×10^{-4} [134]
	Human norovirus G1	7.65	1.5×10^{-4}	1.5×10^{-4} [74]
	Tobacco etch virus	9.49	1.2×10^{-5}	3.0×10^{-5} [135], 4.8×10^{-6} [136]
	Hepatitis C virus	9.65	3.8×10^{-5}	1.2×10^{-4} [137], 2.5×10^{-5} [138], 2.0×10^{-5} [138], 3.5×10^{-5} [105]
ss(-)RNA	Murine hepatitis virus	31.4	3.5×10^{-6}	3.5×10^{-6} [139]
	Vesicular stomatitis virus	11.2	3.7×10^{-5}	6.9×10^{-5} [140, 141], 1.8×10^{-5} [142], 4.2×10^{-5} [143]
	Influenza A virus	13.6	2.5×10^{-5}	4.5×10^{-5} [144], 7.1×10^{-6} [145], 3.9×10^{-5} [146], 3.1×10^{-5} [147]
dsRNA	Measles virus ^d	15.9	3.5×10^{-5}	2.8×10^{-5} [148], 4.4×10^{-5} [149]
	Bacteriophage Φ 6	13.4	1.6×10^{-6}	1.6×10^{-6} [82]
Reverse transcribing	Duck hepatitis B virus	3.03	2.0×10^{-5}	2.0×10^{-5} [150]
	Spleen necrosis virus	7.80	3.7×10^{-5}	2.4×10^{-5} [151], 5.8×10^{-5} [152]
	Murine leukemia virus	8.33	3.0×10^{-5}	6.0×10^{-6} [153], 4.2×10^{-5} [154], 1.1×10^{-4} [155, 156]
	Bovine leukemia virus	8.42	1.7×10^{-5}	1.7×10^{-5} [157]
	Human T-cell leukemia virus	8.50	1.6×10^{-5}	1.6×10^{-5} [158]
	HIV-1 (free virions)	9.18	6.3×10^{-5}	4.9×10^{-5} [76, 159, 160], 1.0×10^{-4} [161], 8.7×10^{-5} [162], 4.4×10^{-5} [163], 3.6×10^{-5} [99], 9.3×10^{-5} [63]
	HIV-1 (cellular DNA)	9.18	4.4×10^{-3}	4.4×10^{-3} [63]
	Foamy virus	13.2	2.1×10^{-5}	2.1×10^{-5} [164]
	Rous sarcoma virus	9.40	1.4×10^{-4}	1.4×10^{-4} [165]
ssDNA	Bacteriophage Φ X174	5.39	1.1×10^{-6}	1.3×10^{-6} [166], 1.0×10^{-6} [23]
	Bacteriophage m13	6.41	7.9×10^{-7}	7.9×10^{-7} [94]
dsDNA	Bacteriophage λ	48.5	5.4×10^{-7}	5.4×10^{-7} [167, 168]
	Herpes simplex virus	152	5.9×10^{-8}	5.9×10^{-8} [169, 170]
	Bacteriophage T2	169	9.8×10^{-8}	9.8×10^{-8} [167, 171]
	Human cytomegalovirus	235	2.0×10^{-7}	2.0×10^{-7} [20]

^a Geometric mean of the individual estimates

^b Mutation rates were normalized to s/n/c units as detailed in previous work [1]

^c This corresponds to a consensus estimate from several studies, see original publication for details

^d Assuming linear replication, see original references for details

other selective factors. For instance, inefficient methylation of the phage DNA may render it susceptible to cleavage by MutH, therefore imposing a selection pressure against GATC sequence motifs [24].

As opposed to bacteriophage ϕ X174, the link between post-replicative repair and mutation rate is still unclear in eukaryotic viruses. Numerous studies have shown that viruses interact with DNA damage response (DDR) pathways by altering the localization or promoting the

degradation of DDR components [25, 26]. For instance, the adenoviral E4orf6 protein promotes proteasomal degradation of TOPBP1, a DDR component [27]. DDR activation can occur as an indirect consequence of cellular stress due to the infection per se or as a part of an antiviral response, which would be in turn counteracted by viruses. Although DNA viruses tend to promote genomic instability in the host cell, it remains to be shown whether DDR dysregulation can determine DNA virus mutation rates.




Fig. 2 Mutation rate variation across viruses. **a** Range of variation of mutation rates for the seven Baltimore classes of viruses (*ss* single-strand, *ds* double-strand; +/− genome polarity, *RT* retroviruses, *pRT* para-retroviruses). In the *RT* group, all mutation rates fall in the *non-hatched arrow* region except the HIV-1 mutation rate measured in cellular DNA, which is orders of magnitude higher than the rate measured in plasma. This is because many APOBEC-edited viral genomes fail to produce viable progeny and hence do not reach

plasma (see text for details). **b** Negative correlation between genome size and mutation rate in viruses. Baltimore groups are indicated. The observed correlation can be explained in terms of differences between RNA and DNA viruses and between *ss* and *ds* viruses. In the *RT* group, the extremely high mutation rate of HIV-1 in cellular DNA is indicated with an *arrow*. In contrast, the HIV-1 mutation rate measured in plasma falls within the usual *RT* range

Viruses with smaller genomes tend to mutate faster

A general inverse correlation between genome size and mutation rate applies to DNA-based microorganisms including viruses, bacteria and unicellular eukaryotes [28]. According to this rule, the per-genome mutation rate stays relatively constant at a value of approximately 0.003 per round of copy. A similar negative relationship seems to exist in RNA viruses, but their smaller genome size range of variation makes it more difficult to detect such trend (Fig. 2b). Supporting this correlation, however, coronaviruses have the largest genomes among RNA viruses (30–33 kb) and have evolved proofreading capacity, as opposed to all other RNA viruses known [11]. Conversely, one of the highest mutation rate described for a ribovirus corresponds to bacteriophage Q β , which has one of the smallest RNA genomes [29]. Therefore, there appears to be a general negative correlation between mutation rates and genome size in microorganisms. However, the underlying causes remain unclear, both at the mechanistic and evolutionary levels. First, there are no known differences in intrinsic replication fidelity among the polymerases of different RNA viruses (excepting coronavirus exonuclease activity). Second, in DNA viruses, those with higher estimated mutation rates have smaller genomes, but also have single-strand DNA (Fig. 2). Estimates for small double-strand DNA viruses would be needed to clarify which of these two factors contributes more to elevating mutation rates. The observation that most highly variable and rapidly evolving DNA viruses have small genomes (including

double-strand viruses) indirectly supports an effect of genome size [3].

Candidate mechanisms that might account for mutation rate differences between large and small DNA viruses may involve virus–DDR interactions. Whereas many viruses appear to evade DDR, others seem to use it for their own benefit [25, 26]. Polyomaviruses, papillomaviruses and parvoviruses induce and depend on DDR signaling pathways for efficient replication [30–32]. These viruses share the property of having small, circular DNA genomes which do not encode a polymerase. As such, they depend directly on the cellular replication machinery, as opposed to larger DNA viruses. It is possible that some small viruses promote the DDR to prolong the S cell-cycle phase, which offers a more favorable environment for replication. By adopting circular genomes, these viruses would also avoid the formation of genome concatemers, a typical effect of DDR in linear viral genomes such as, for instance, adenoviruses [33]. Whether differences in DDR activation between small/circular and large/linear DNA viruses translate into mutation rate differences remains to be tested. The DDR comprises error-prone DNA polymerases for re-synthesis of excised strands [34], and involvement of these polymerases in viral replication may lead to higher mutation rates.

Polymerase fidelity variants

Intrinsic polymerase fidelity (i.e., the ability to incorporate the correct base and exclude incorrect bases from the active site during DNA synthesis) is a primary mutation rate

determinant. Polymerase variants with altered fidelity have been artificially selected in a number of RNA viruses by subjecting laboratory populations to mutagenic treatments [35]. For instance, serial passaging of poliovirus in the presence of the base analog ribavirin led to the selection of a polymerase variant (G64S) with threefold increased fidelity [36]. This same mutation also confers increased fidelity in the related human enterovirus 71 [37], and other amino acid replacements such as L123F have also been shown to modify the replication fidelity of this virus [38]. Passaging of coxsackievirus B3 (also a member of the enterovirus genus in the picornavirus family) in the presence of ribavirin or 5-azacytidine selected for another fidelity variant in the viral polymerase (A372V) [39]. Outside picornaviruses, fidelity variants have been more recently obtained by serial mutagen treatment in chikungunya virus [40], influenza A virus [41], and West Nile virus [42]. Several antivirals and notably many antiretroviral drugs are base analogs. Resistance to these treatments is well documented in the HIV-1 RT and some of these variants modify replication fidelity, as determined in vitro or in cell cultures [13]. Intrinsic fidelity can be determined by residues located inside or outside the catalytic domain [43, 44]. For instance, reorientation of the triphosphate moiety of the incoming nucleotide is a fidelity checkpoint in poliovirus polymerase [45]. Interestingly, recent work has shown that replication fidelity can also be determined by proteins of the replication complex other than the viral polymerase. Serial passages of chikungunya virus in the presence of nucleoside analogs favored the appearance of substitution G641D in the RNA helicase nsP2 [40]. This variant increased replication fidelity through mechanisms linked to reduced helicase activity, increased replication kinetics, and resistance to low nucleotide concentrations [46]. Fidelity variants demonstrate the ability of RNA viruses to evolutionarily adjust mutation rates in response to selection acting on mutation rate or other traits.

DNA virus mutation rates also respond to selection, as shown in earlier work with bacteriophage T4 in which a series of polymerase variants were identified following chemical mutagenesis [47]. T4 polymerase variants showing strongly increased fidelity have been described (as opposed to more modest effects in RNA viruses) and tend to map to the central palm and the carboxyl-terminal thumb subdomain of the viral polymerase. Mutator phenotypes have also been described in T4. This phenotype can be conferred by changes in replication factors such as single stranded DNA-binding proteins or helicase proteins [48]. However, the strongest mutator phenotypes (up to 400-fold increase in mutation rate) often result from 3' exonuclease inactivation in T4 [47]. Similar results were obtained with herpes simplex virus type 1 (HSV-1), for which mutations in the conserved regions of the polymerase domain were

found to modify replication fidelity. A HSV-1 polymerase mutant containing Y577H/D581A substitutions was exonuclease-deficient and exhibited a mutator phenotype. However, this variant rapidly evolved a compensatory substitution (L774F) that restored DNA replication fidelity in this genetic background [49, 50]. Since RNA virus polymerases typically lack this activity, no such mutators can be produced, except for coronaviruses [51]. Furthermore, the genetic diversity of RNA viruses is probably closer to an upper tolerability limit beyond which the population genetic load increases to levels incompatible with virus survival [3, 52]. Therefore, both biochemical and population-genetic factors limit the appearance of strong mutators in RNA viruses.

Host-encoded mutation rate modifiers in RNA and reverse-transcribing viruses

Whereas post-replicative repair probably plays a role in determining DNA virus mutation rates (as discussed above), RNA virus mutation rates are strongly influenced by other host-encoded factors. Apolipoprotein B mRNA-editing catalytic polypeptide-like enzymes (APOBEC) are a family of cellular cytidine deaminases that function as an innate cellular defense against retroviruses [53]. This family has expanded and diverged throughout vertebrate evolution and includes five APOBECs [54]. APOBEC3G was first shown to massively convert cytidines to uracils in the complementary HIV-1 DNA during or following reverse transcription [55–57]. APOBEC activity is antagonized by the viral protein Vif, which binds to and promotes the proteasomal degradation of APOBEC [58]. There are seven APOBEC3 paralogs in the human genome (A–D and F–H) which have been shown to also edit retroelements and other viruses, including hepatitis B virus [59], papillomaviruses [60], and herpesviruses [61]. Editing is strongly dependent on sequence-context. The major determinant of editing for human APOBECs is the –1 base, thus defining typical dinucleotide targets (the edited base and the –1 base). APOBEC3G prefers CC dinucleotides whereas the other APOBEC forms prefer TC dinucleotides. DNA editing hotspots have been identified and depend both on sequence context and DNA secondary structure [62]. In HIV-1, editing of the complementary DNA strand produces GG-to-AG or GA-to-AA mutations in the genomic RNA. In recent work, we have estimated the relative contributions of host APOBECs and the viral RT to the total HIV-1 mutation rate in vivo [63]. We found that the vast majority of mutations (98 %) are produced by APOBECs and that this elevates the HIV-1 mutation rate by >40-fold above the RT error rate, making HIV-1 the fastest mutating virus described so far. In many cases,

hyper-mutation leads to loss of infectivity and hence effectively exerts its antiviral action. However, APOBECs can also produce moderately mutated, viable viruses, thus raising the question whether these deaminases may contribute to viral diversity and evolution, immune escape, and drug resistance [64–66].

Double-strand RNA-dependent adenosine deaminases (ADARs) are another type of host enzymes that edit viral genomes by deaminating adenosines in long double-stranded RNA and converting them to inosines. The latter base-pair with guanosines, resulting in A-to-G base substitutions [67]. ADARs also exhibit sequence context preferences, although less marked than in the case of APOBECs [68]. ADAR-driven hyper-mutation was first demonstrated in measles virus [69] and has since been suggested for a variety of RNA viruses including human parainfluenza virus [70], respiratory syncytial virus [71], lymphocytic choriomeningitis virus [72], Rift Valley fever virus [73], and noroviruses [74].

Lastly, other cellular proteins such as uracil DNA glycosylases (UNG) can modulate viral mutation rates. Uracil can be found in DNA abnormally due to spontaneous or enzymatically induced cytidine deamination, leading to G-to-A mutations. To avoid the deleterious effects of uracil in DNA, UNG recognizes and excises uracil residues present in DNA. The HIV-1 protein Vpr interacts with UNG and mediates its incorporation into HIV-1 virions. Failure to incorporate UNG produces a fourfold increase of the HIV-1 mutation rate in actively dividing cells, and of 18-fold in macrophages [75, 76]. Variations in the concentration and balance of dNTPs among cell types may also influence viral mutation rates [77]. Although analysis of HIV-1 mutations in various cell lines revealed no obvious mutation rate differences, it nevertheless showed differences in the type of mutations produced [78].

Mutation accumulation is determined by replication mode

In contrast to cells, viruses can adopt a variety of replication modes. Replication is said to follow a “stamping machine” model if a single template is used to produce all progeny strands within a given cell (Fig. 3a). Under this theoretical model, there is only one round of copying per cell. In practice, this means that each infecting genome is used to synthesize a single reverse-complementary intermediate which in turn is used as template for synthesizing all progeny genomes. This contrasts with semi-conservative replication, in which each strand is copied once to produce progeny molecules that are, in turn, used as templates in the next round of copying. Since under semi-conservative replication the number of strands doubles in

each cycle, the virus necessarily has to undergo multiple replication cycles within each cell to produce enough progeny. Under stamping machine replication the mutation frequency observed after one cell infection equals the mutation rate, but under semi-conservative replication this frequency is also determined by the number of replication cycles, as mutants become amplified. This means that a given viral polymerase will produce more mutations per cell if replication is semi-conservative than if replication is stamping machine-like. These two models are indeed two extremes of a continuum of possible replication modes. For instance, a virus can produce multiple progeny molecules per round of copying which then undergo a second replication cycle in the same cell to end up producing hundreds or thousands of progeny molecules.

It has been suggested that the stamping machine model has been selectively favored in RNA viruses because it compensates for the extremely high error rate of their polymerases [79–81]. Some RNA viruses such as bacteriophage $\phi 6$ [82], bacteriophage Q β [83] and turnip mosaic virus [84] tend to replicate via the stamping machine model. However, empirically-informed modeling of the poliovirus replication cycle indicated multiple rounds of copying per cell [85]. Similarly, single-cell analysis of the genetic diversity produced by vesicular stomatitis virus revealed that some mutations are amplified within cells, implying that multiple rounds of copying take place per cell [86]. However, it remains unknown whether a given virus can modify its replication mode in response to specific selective pressures in order to promote or down-regulate mutational output. To a large extent, the replication mode of most viruses should be dictated by the molecular mechanisms of replication and, hence, should be subjected to strong functional constraints. For instance, bacteriophage $\phi X174$ replicates via the stamping machine mode because it uses rolling circle replication [87, 88]. In contrast, semi-conservative replication is probably the only mechanistically feasible replication model for viruses with large DNA genomes.

Lysis time as a regulator of mutational output

Changes in lysis time can be thought of as another mechanism for regulating the production of mutations in viral populations. Lysis is a tightly regulated process and, in theory, viral fitness is maximized for some intermediate lysis time [89–91]. If lysis occurs before this optimum, the infected cell will release a small amount viral progeny and hence few cells will be infected in the next infection cycle, retarding population growth. Yet if lysis occurs after the optimum, a large amount of progeny will be produced per cell but cell-to-cell transmission will be delayed. The




Fig. 3 Viral replication modes and mutation accumulation. **a** Stamping machine versus semi-conservative replication. As opposed to cells, which use only semi-conservative replication, viruses can adopt a variety of replication modes. In the stamping machine model, a single template strand is used to synthesize all progeny genomes within a given cell. However, this is not possible in practice because replication requires synthesis of complementary strands or “anti-genomes” (blue). Under this model, the mutation frequency after one cell infection cycle will equal the mutation rate except if mutations occur during the first round of copying (from genome to anti-genome), in which case they will be present in all of the viral progeny. Under semi-conservative replication, multiple rounds of copying are required to produce enough progeny, thus allowing for the intra-cellular accumulation of mutations. **b** Relationship between lysis time and mutation accumulation. Longer cell infection cycles (late burst) can allow for the production of more progeny viruses. Under semi-conservative replication, this will require more rounds of copying but, if replication follows the stamping machine model, the number of rounds of copying will not change (more progeny genomes will be produced from the same template). Hence under this model, a late-burst virus variant will undergo fewer total rounds of copying at the population scale than early-burst variants and will tend to accumulate fewer mutations

optimal lysis time depends on the time required to start producing progeny virions (lag/eclipse time), the capacity of infected cells to produce virions (yield) and virus/host population densities (multiplicity of infection). However, the optimum can also vary according to mutation rate. Bacteriophage ϕ X174 experimental populations treated with the nucleoside analog 5-fluorouracil showed increased mutation frequency and reduced growth [92]. As opposed to other viruses, polymerase fidelity variants cannot evolve in response to this type of treatment because bacteriophage ϕ X174, as well as other small DNA viruses, does not code for a polymerase. Interestingly, 5-fluorouracil selected for

an amino acid replacement in the N-terminal region of the phage lysis protein (V2A). This change conferred partial resistance to the drug, but also delayed lysis [93]. In turn, delayed lysis was concomitant with an increase in the viral yield per cell, since progeny virions had more time to accumulate intracellularly. Therefore, at the population level, growth of the V2A variant occurred through longer infection cycles with increased per-cell productivity. However, because the virus replicates following a stamping machine model, each infection cycle should involve only one round of copying regardless of lysis time. As a result, population growth required fewer total rounds of copying in the delayed lysis variants than in the wild-type, meaning that mutations had fewer opportunities to accumulate (Fig. 3b). Therefore, delayed lysis increased the ability of the phage to tolerate mutagenesis.

Template-dependent effects on mutation rate

The fidelity of a given polymerase varies according to certain template properties. It is well known that misalignments at homopolymeric runs can cause frameshift mutations and base substitutions [94]. Sequence context may influence the fidelity of HIV-1 RT by modulating enzyme binding and dissociation [95]. Also, RNA secondary structures have been shown to promote template switching, a process that does not lead to new mutations but produces recombinant viruses [96–98]. In recent work, we found that RNA structure can also modulate the fidelity of HIV-1 RT [99]. Shuttle vectors are systems in which most or all sequences except essential cis-acting elements (such as the Rev-responsive element or long terminal repeats) have been removed from the viral genome. Shuttle vectors allow propagating HIV-1 in the absence of selection because all required functions are provided in trans by helper plasmids that are freshly provided in each infection cycle [100] (Fig. 4a). The shuttle vector simply carries forward sequences of interest, which can be reporter genes for selecting and visualizing transduced cells, or transgenes for engineering purposes. However, the vector also accepts HIV-1 sequences. These will have no role in the infection cycle, as they are not expressed. Because selection is absent, such HIV-1 sequences cloned in a shuttle vector can be used for interrogating the viral mutation rate in cognate templates, which is helpful for testing the effects of sequence context or RNA structure on mutation rate.

Using this system, we recently characterized the distribution of mutations along the HIV-1 envelope, integrase, *vif*, and *vpr* genes [99]. We found that a 1 kb region encompassing the V1–V5 loops of the gp120 envelope protein accumulated approximately three times fewer mutations than other regions of the HIV-1 genome. This

coldspot mapped to the outermost domains of gp120, which are preferred targets of circulating antibodies and show extensive glycosylation. Examination of this region revealed two differential properties. First, it contained fewer-than-expected GG and GA dinucleotides, which are the preferred sequence contexts of APOBEC3, as previously discussed [101, 102]. As a result, APOBEC-driven G-to-A mutations were less frequent in V1–V5 than in other genome regions. Second, using the RNA structure morel previously determined by selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE), we found that this 1 kb region exhibited significantly fewer RNA base-pairs than other regions of the envelope gene [103]. To more directly test the effect of RNA structure on HIV-1 RT fidelity, we used in vitro polymerization assays with two different templates: a random sequence and RNA from potato spindle tuber viroid, which shows a marked, stem-like secondary structure [104]. We found an increased RT error rate in the viroid RNA compared to the random sequence, suggesting that RT fidelity decreases in highly structured RNA.

Using a conceptually similar approach, we recently characterized the accumulation of mutations along the HCV genome under weak or no selection using a bicistronic replicon by cloning HCV sequences at a site commonly used for inserting reporter genes (Fig. 4b). This revealed extreme mutation rate variations across individual nucleotide sites of the viral genome, with differences of orders of magnitude even between adjacent sites [105]. In

that system, we found little or no effect of RNA structure on mutation rate, but a more significant effect of base identity, such that A and U bases were more prone to mutation than G and C.

Targeted hyper-mutation in viruses

The finding that HIV-1 has a reduced mutation rate in the genome region encoding the outermost domains of the gp120 envelope protein reveals an uncoupling between mutation rate and genetic diversity, as these domains are the most variable regions of the HIV-1 genome, mainly as a consequence of immune pressure [106]. This indicates that HIV-1 has not evolved the ability to target mutation to regions wherein they are more likely to be needed for adaptation. A possible evolutionary explanation for the gp120 V1–V5 coldspot is that some APOBEC-driven mutations favored by immune pressure during HIV-1 evolutionary history resulted in loss of APOBEC targets, leading to a subsequent reduction in mutation rate. Similarly, strong selection at the protein level may have favored amino acid replacements within this region even at the cost of disrupting pre-existing RNA secondary structures and, as a consequence, these RNA structural changes would have modified replication fidelity [99]. In HCV, we found no significant differences in mutation rate across genes [105], as opposed to genetic variation, which concentrates in specific genomes regions including external domains of




Fig. 4 Cell culture systems for the accumulation of mutations in the absence of selection. **a** HIV-1 shuttle vector. The vector contains only cis-acting HIV-1 sequences such as the Rev-responsive element (RRE), the encapsidation signal (Ψ), and the long terminal repeats (LTR). A resistance gene (RES, red) is inserted to allow for the selection of cells containing the vector. Any (short) sequence of interest (SEQ, blue), including HIV sequences, can be cloned in the shuttle vector and propagated in the absence of selection. The shuttle vector DNA is co-transfected with helper plasmids encoding the Gag (capsid) and Pol (RT, integrase) proteins as well as a viral glycoprotein suited for transducing a given cell line (here vesicular stomatitis G protein, VSV-G, which has a broad tropism). Pseudotyped viruses are produced, used for transduction, and cells carrying the retroviral shuttle vector are selected with the appropriate antibiotic. The infection cycle can be restarted at any time by

transfecting the two helper plasmids. The SEQ DNA is then extracted, PCR-amplified, and sequenced to score mutations. **b** HCV replicon. Two cistrons are separated by an internal ribosome entry site (IRES). The right cistron encodes HCV non-structural (NS) proteins required for replication, but lacks the envelope proteins and hence does not support viral budding. The left replicon carries a resistance gene to select cells carrying the replicon. Reporters such as luciferase can be also cloned in this cistron. Since these play no function, they can be replaced with any short sequence of interest (SEQ), including HCV sequences. Replicon RNA is obtained by in vitro transcription and transfected into Huh7 hepatoma cells. Cells are selected using the appropriate antibiotic and passaged before confluence to allow vigorous replication of the viral RNA. The SEQ RNA is reverse-transcribed, PCR-amplified, and sequenced to score mutations

the E2 envelope protein [107]. This again supports the view that RNA viruses cannot target mutations to specific genomes regions to improve their adaptability.

This contrasts with bacteria and DNA viruses, in which mechanisms of error-prone replication have evolved at specific *loci* involved in host-pathogen interactions [108–110]. A well-characterized system of mutation targeting, called diversity-generating retro-elements (DGRs), is found in large DNA bacteriophages [110]. DGRs are typically located in genes involved in host attachment, a step of the infection cycle that is subject to rapid changes depending on host species availability. DGRs were first identified in the *Bordetella* BPP-1 bacteriophage [111], and always contain two sequence repeats called variable repeat (VR) and template repeat (TR). The BPP-1 VR is located in the 3' end of the *mtd* gene (major tropism determinant), which encodes a tail fiber protein. The TR is located downstream of the VR and has a highly conserved sequence, in contrast to the VR. An RT is also encoded by the DGR and synthesizes a cDNA from the TR transcript, a process during which extensive mutagenesis of adenines takes place by a key unknown mechanism. The cDNA is then transferred to the VR, producing a large number of variants of the *mtd* gene capable of interacting with new host ligands [112]. Some hypervariable genes in DNA viruses from the human lower gastrointestinal tract show homology with the BPP-1 DGR, and most of these *loci* are linked to RT genes, suggesting the presence of DGRs [113]. DGRs have also been described in plasmids, bacterial and archaeal chromosomes, and archaeal viruses [114–116]. It therefore appears that at least some prokaryotic DNA viruses have evolved the ability to target mutations to specific regions, as opposed to RNA viruses.

Interplays between mutation and recombination

Diversity-generating retro-elements have not been described in eukaryotic viruses, but these viruses can use other mechanisms of mutational targeting that involve recombination. The inverted terminal repeats of vaccinia virus contain 10–100 base repeated sequence motifs known to experience frequent unequal crossover events and rapid changes in copy number [117, 118]. Recombination has been shown to promote the rapid production of genetic diversity in other genome regions of the vaccinia virus involved in immune escape and the colonization of novel hosts. Protein kinase R (PKR) is a central effector of innate antiviral immunity that induces translational shutoff, modifies protein phosphorylation status, alters mRNA stability, and induces apoptosis [119]. Poxvirus proteins K3L and E3L block PKR and have evolved as antagonists of innate immune responses in a host-specific manner

[120, 121]. Experimental deletion of E3L renders vaccinia virus more susceptible to host antiviral responses, imposing a strong selection pressure in the other PKR suppressor K3L to increase its function [108]. Serial transfers of E3L-deleted vaccinia virus led to an elevated K3L copy number, a recombination-driven process that allowed the virus to overexpress this gene. This gain-of-function mutation had a direct fitness benefit, but also increased the number of available targets for the appearance of subsequent selectively advantageous point mutations in K3L. Remarkably, upon selection of these mutants K3L copy numbers were again reduced. Hence, recombination led to an evolutionary process characterized by expansion and contraction of a specific genome region. These so-called genomic accordions have been posited to mediate adaptive duplications in other poxviruses such as myxoma virus [122].

Interesting interplays between recombination and mutation rates have also been recently found in RNA viruses. These two processes are primarily controlled by the viral polymerase since, in RNA viruses, recombination takes place when the viral polymerase switches between different template genomes present in the same cell [123]. The estimated recombination rates of different riboviruses and retroviruses correlate positively with estimated mutation rates [124]. High mutation rates confer viruses the ability to rapidly produce advantageous mutations, but also inflate the genetic load of the population. In turn, frequent recombination allows beneficial mutations to unlink from deleterious genetic backgrounds, as well different beneficial mutations to be combined into the same genome. As such, recombination is expected to enhance adaptation when a large number of alleles coexist in the same population, a scenario that typically takes place at high mutation rates [125]. Experimental evidence supporting the joint effects of recombination and mutation rates in viral adaptability has been recently obtained using poliovirus polymerase mutants that individually alter replication fidelity or recombination rate [126]. In another recent work, a low-fidelity variant of Sindbis virus was found to exhibit increased recombination [127]. This variant showed low fitness and a greater tendency to accumulate defective interfering particles (i.e. mutant viruses with large deletions that depend on and interfere with the wild-type infection cycle). Therefore, it appears that high mutation and recombination rates enhance viral adaptability, but only up to a certain point, beyond which both processes contribute to the accumulation of deleterious alleles in the population.

Conclusions

Viral mutation rates are determined by multiple processes, including polymerase intrinsic fidelity, replication mode, 3' exonuclease activity, spontaneous nucleic acid damage,

Table 2 Molecular determinants of viral mutation rates

	Higher mutation rate	Lower mutation rate
Global genomic features	RNA, single-strand, short	DNA, double-strand, large
Specific template features	RNA base-pairs, sequence repeats	–
Replication mode	Semi-conservative	Stamping machine
Fidelity mechanisms	–	3' Exonuclease, repair
Host-encoded proteins	APOBEC, ADAR	UNG, MutHLS/Dam
Other host factors	Unbalanced dNTP pools, ROS	–

access to post-replicative repair, editing by host-encoded deaminases, imbalances in nucleotide pools, template sequence context, and template structure, as summarized in Table 2. Some of these processes underlie large-scale patterns of variation among viruses, such as differences between RNA and DNA viruses, between viruses with small and large genomes, and between single-strand and double-strand viruses, but important mechanistic aspects behind these differences still remain uncharacterized. Furthermore, mutation rates are not static and can evolve in response to selective pressures, as exemplified by fidelity variants selected under mutagenic conditions in a variety of viruses. In addition to polymerase fidelity, other mutation rate-determinants such as access to DNA repair may have also changed in response to selective pressures during viral evolution.

In RNA viruses, both low- and high-fidelity polymerase variants tend to have a negative impact in viral fitness in complex environments, suggesting that RNA virus mutation rates have been evolutionarily optimized. Given that DNA virus mutation rates are substantially lower than those of RNA viruses this also suggests that DNA viruses show suboptimal mutation rates for adaptation to rapidly changing environments, despite RNA and DNA viruses sharing similar lifestyles. It appears that large DNA viruses have adopted a different and more elaborate strategy consisting of targeting mutations to specific genome regions subject to rapidly varying selective pressures, such as genes encoding attachment proteins or inhibitors of innate immunity responses. Mutation targeting mechanisms such as DGRs and recombination-driven gene copy amplification are probably not accessible to small DNA viruses with compact genomes. Furthermore, mutation rate evolution in small DNA viruses is further constrained by the fact they do not encode autonomous replication systems. Therefore, small DNA viruses should rely on repair avoidance and on use of host-encoded error-prone DNA polymerases to elevate their mutation rates and achieve faster adaptation.

Elucidating the mutational mechanisms of small DNA viruses is a current challenge in virus molecular biology and evolution. Other exciting unresolved questions include unveiling the interplays between mutation and recombination, the roles played by viral accessory proteins in determining mutation rates, the effects of host-encoding enzymes on viral diversity and evolution, whether mutation accumulation can be evolutionary adjusted by modifying viral replication modes, and how template sequences regulate viral mutation rates.

Acknowledgments This work was supported by grants from the Spanish MINECO (BFU2013-41329) and the European Research Council (ERC-2011-StG-281191-VIRMUT) to R.S.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

- Sanjuán R, Nebot MR, Chirico N, Mansky LM, Belshaw R (2010) Viral mutation rates. *J Virol* 84:9733–9748
- Duffy S, Shackelton LA, Holmes EC (2008) Rates of evolutionary change in viruses: patterns and determinants. *Nat Rev Genet* 9:267–276
- Sanjuán R (2012) From molecular genetics to phylodynamics: evolutionary relevance of mutation rates across viruses. *PLoS Pathog* 8:e1002685
- Perelson AS (2002) Modelling viral and immune system dynamics. *Nat Rev Immunol* 2:28–36
- Pawlotsky JM (2016) Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. *Gastroenterology* 151:70–86
- Cao Y, Bao Y, Xia W, Wu H, Wei F, Zhang Y, Zhang R, Xu X (2016) Resistance-associated mutations to HCV protease inhibitors naturally pre-existed in HIV/HCV coinfecting, treatment-naive patients. *Clin Res Hepatol Gastroenterol*. doi:10.1016/j.clinre.2016.02.004
- Coppola N, Onorato L, Minichini C, Di CG, Starace M, Sagnelli C, Sagnelli E (2015) Clinical significance of hepatitis B surface antigen mutants. *World J Hepatol* 7:2729–2739
- Schotsaert M, García-Sastre A (2014) Influenza vaccines: a moving interdisciplinary field. *Viruses* 6:3809–3826
- Roberts JD, Bebenek K, Kunkel TA (1988) The accuracy of reverse transcriptase from HIV-1. *Science* 242:1171–1173
- Steinhauer DA, Domingo E, Holland JJ (1992) Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. *Gene* 122:281–288
- Smith EC, Sexton NR, Denison MR (2014) Thinking outside the triangle: replication fidelity of the largest RNA viruses. *Annu Rev Virol* 1:111–132
- Hong YB, Choi Y, Jung G (2004) Increased DNA polymerase fidelity of the Lamivudine resistant variants of human hepatitis B virus DNA polymerase. *J Biochem Mol Biol* 37:167–176
- Menéndez-Arias L (2009) Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. *Viruses* 1:1137–1165

14. Biek R, Pybus OG, Lloyd-Smith JO, Didelot X (2015) Measurably evolving pathogens in the genomic era. *Trends Ecol Evol* 30:306–313
15. Shackelton LA, Parrish CR, Truyen U, Holmes EC (2005) High rate of viral evolution associated with the emergence of carnivore parvovirus. *Proc Natl Acad Sci USA* 102:379–384
16. Shackelton LA, Holmes EC (2006) Phylogenetic evidence for the rapid evolution of human B19 erythrovirus. *J Virol* 80:3666–3669
17. Duffy S, Holmes EC (2008) Phylogenetic evidence for rapid rates of molecular evolution in the single-stranded DNA begomovirus tomato yellow leaf curl virus. *J Virol* 82:957–965
18. Sarker S, Patterson EI, Peters A, Baker GB, Forwood JK, Ghorashi SA, Holdsworth M, Baker R, Murray N, Raidal SR (2014) Mutability dynamics of an emergent single stranded DNA virus in a naive host. *PLoS One* 9:e85370
19. Michaud V, Randriamparany T, Albina E (2013) Comprehensive phylogenetic reconstructions of African swine fever virus: proposal for a new classification and molecular dating of the virus. *PLoS One* 8:e69662
20. Renzette N, Pokalyuk C, Gibson L, Bhattacharjee B, Schleiss MR, Hamprecht K, Yamamoto AY, Mussi-Pinhata MM, Britt WJ, Jensen JD, Kowalik TF (2015) Limits and patterns of cytomegalovirus genomic diversity in humans. *Proc Natl Acad Sci USA* 112:E4120–E4128
21. Seronello S, Montanez J, Presleigh K, Barlow M, Park SB, Choi J (2011) Ethanol and reactive species increase basal sequence heterogeneity of hepatitis C virus and produce variants with reduced susceptibility to antivirals. *PLoS One* 6:e27436
22. Jiricny J (2013) Postreplicative mismatch repair. *Cold Spring Harb Perspect Biol* 5:a012633
23. Cuevas JM, Duffy S, Sanjuán R (2009) Point mutation rate of bacteriophage Φ X174. *Genetics* 183:747–749
24. Deschavanne P, Radman M (1991) Counterselection of GATC sequences in enterobacteriophages by the components of the methyl-directed mismatch repair system. *J Mol Evol* 33:125–132
25. Luftig MA (2014) Viruses and the DNA damage response: activation and antagonism. *Annu Rev Virol* 1:605–625
26. Weitzman MD, Lilley CE, Chaurushiya MS (2010) Genomes in conflict: maintaining genome integrity during virus infection. *Annu Rev Microbiol* 64:61–81
27. Blackford AN, Patel RN, Forrester NA, Theil K, Groitl P, Stewart GS, Taylor AM, Morgan IM, Dobner T, Grand RJ, Turnell AS (2010) Adenovirus 12 E4orf6 inhibits ATR activation by promoting TOPBP1 degradation. *Proc Natl Acad Sci USA* 107:12251–12256
28. Lynch M (2010) Evolution of the mutation rate. *Trends Genet* 26:345–352
29. Bradwell K, Combe M, Domingo-Calap P, Sanjuán R (2013) Correlation between mutation rate and genome size in riboviruses: mutation rate of bacteriophage Φ B. *Genetics* 195:243–251
30. Dahl J, You J, Benjamin TL (2005) Induction and utilization of an ATM signaling pathway by polyomavirus. *J Virol* 79:13007–13017
31. Gillespie KA, Mehta KP, Laimins LA, Moody CA (2012) Human papillomaviruses recruit cellular DNA repair and homologous recombination factors to viral replication centers. *J Virol* 86:9520–9526
32. Luo Y, Qiu J (2013) Parvovirus infection-induced DNA damage response. *Future Virol* 8:245–257
33. Weiden MD, Ginsberg HS (1994) Deletion of the E4 region of the genome produces adenovirus DNA concatemers. *Proc Natl Acad Sci USA* 91:153–157
34. Ciccía A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. *Mol Cell* 40:179–204
35. Bordería AV, Rozen-Gagnon K, Vignuzzi M (2015) Fidelity variants and RNA quasispecies. *Curr Top Microbiol Immunol* 392:303–322
36. Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. *Proc Natl Acad Sci USA* 100:7289–7294
37. Sadeghipour S, Bek EJ, McMinn PC (2013) Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. *J Virol* 87:1759–1769
38. Meng T, Kwang J (2014) Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. *J Virol* 88:5803–5815
39. Levi LI, Gnadig NF, Beaucourt S, McPherson MJ, Baron B, Arnold JJ, Vignuzzi M (2010) Fidelity variants of RNA dependent RNA polymerases uncover an indirect, mutagenic activity of amiloride compounds. *PLoS Pathog* 6:e1001163
40. Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M (2011) Arbovirus high fidelity variant loses fitness in mosquitoes and mice. *Proc Natl Acad Sci USA* 108:16038–16043
41. Cheung PP, Watson SJ, Choy KT, Fun SS, Wong DD, Poon LL, Kellam P, Guan Y, Malik Peiris JS, Yen HL (2014) Generation and characterization of influenza A viruses with altered polymerase fidelity. *Nat Commun* 5:4794
42. Van Slyke GA, Arnold JJ, Lugo AJ, Griesemer SB, Moustafa IM, Kramer LD, Cameron CE, Ciota AT (2015) Sequence-specific fidelity alterations associated with West Nile virus attenuation in mosquitoes. *PLoS Pathog* 11:e1005009
43. Gong P, Peersen OB (2010) Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. *Proc Natl Acad Sci USA* 107:22505–22510
44. Korneeva VS, Cameron CE (2007) Structure–function relationships of the viral RNA-dependent RNA polymerase: fidelity, replication speed, and initiation mechanism determined by a residue in the ribose-binding pocket. *J Biol Chem* 282:16135–16145
45. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE (2005) Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. *J Biol Chem* 280:25706–25716
46. Stapleford KA, Rozen-Gagnon K, Das PK, Saul S, Poirier EZ, Blanc H, Vidalain PO, Merits A, Vignuzzi M (2015) Viral polymerase-helicase complexes regulate replication fidelity to overcome intracellular nucleotide depletion. *J Virol* 89:11233–11244
47. Mansky LM, Cunningham KS (2000) Virus mutators and antimutators: roles in evolution, pathogenesis and emergence. *Trends Genet* 16:512–517
48. Mufti S (1979) Mutator effects of alleles of phage T4 genes 32, 41, 44, and 45 in the presence of an antimutator polymerase. *Virology* 94:1–9
49. Hwang YT, Liu BY, Coen DM, Hwang CB (1997) Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. *J Virol* 71:7791–7798
50. Tian W, Hwang YT, Lu Q, Hwang CB (2009) Finger domain mutation affects enzyme activity, DNA replication efficiency, and fidelity of an exonuclease-deficient DNA polymerase of herpes simplex virus type 1. *J Virol* 83:7194–7201
51. Smith EC, Blanc H, Vignuzzi M, Denison MR (2013) Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. *PLoS Pathog* 9:e1003565

52. Andino R, Domingo E (2015) Viral quasispecies. *Virology* 479–480C:46–51
53. Harris RS, Dudley JP (2015) APOBECs and virus restriction. *Virology* 479–480C:131–145
54. Munk C, Willemsen A, Bravo IG (2012) An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. *BMC Evol Biol* 12:71
55. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH (2003) DNA deamination mediates innate immunity to retroviral infection. *Cell* 113:803–809
56. Lecossier D, Bouchonnet F, Clavel F, Hance AJ (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. *Science* 300:1112
57. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. *Nature* 424:99–103
58. Desimie BA, Delviks-Frankenberry KA, Burdick RC, Qi D, Izumi T, Pathak VK (2014) Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all. *J Mol Biol* 426:1220–1245
59. Suspène R, Guetard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP (2005) Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. *Proc Natl Acad Sci USA* 102:8321–8326
60. Vartanian JP, Guétard D, Henry M, Wain-Hobson S (2008) Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. *Science* 320:230–233
61. Suspène R, Aynaud MM, Koch S, Pasdeloup D, Labetoulle M, Gaertner B, Vartanian JP, Meyerhans A, Wain-Hobson S (2011) Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. *J Virol* 85:7594–7602
62. Holtz CM, Sadler HA, Mansky LM (2013) APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure. *Nucleic Acids Res* 41:6139–6148
63. Cuevas JM, Geller R, Garijo R, López-Aldegue J, Sanjuán R (2015) Extremely high mutation rate of HIV-1 in vivo. *PLoS Biol* 13:e1002251
64. Monajemi M, Woodworth CF, Zipperlen K, Gallant M, Grant MD, Larijani M (2014) Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8 + T cells. *PLoS One* 9:e93428
65. Sadler HA, Stenglein MD, Harris RS, Mansky LM (2010) APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. *J Virol* 84:7396–7404
66. Fourati S, Malet I, Lambert S, Soulie C, Wirden M, Flandre P, Fofana DB, Sayon S, Simon A, Katlama C, Calvez V, Marcelin AG (2012) E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure. *AIDS* 26:1619–1624
67. Tomaselli S, Galeano F, Locatelli F, Gallo A (2015) ADARs and the balance game between virus infection and innate immune cell response. *Curr Issues Mol Biol* 17:37–51
68. Kuttan A, Bass BL (2012) Mechanistic insights into editing-site specificity of ADARs. *Proc Natl Acad Sci USA* 109:E3295–E3304
69. Cattaneo R, Schmid A, Eschle D, Baczkó K, ter Meulen V, Billeter MA (1988) Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. *Cell* 55:255–265
70. Murphy DG, Dimock K, Kang CY (1991) Numerous transitions in human parainfluenza virus 3 RNA recovered from persistently infected cells. *Virology* 181:760–763
71. Martínez I, Melero JA (2002) A model for the generation of multiple A to G transitions in the human respiratory syncytial virus genome: predicted RNA secondary structures as substrates for adenosine deaminases that act on RNA. *J Gen Virol* 83:1445–1455
72. Zahn RC, Schelp I, Utermohlen O, von Laer D (2007) A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. *J Virol* 81:457–464
73. Suspène R, Renard M, Henry M, Guetard D, Puyraimond-Zemmour D, Billecocq A, Bouloy M, Tangy F, Vartanian JP, Wain-Hobson S (2008) Inverting the natural hydrogen bonding rule to selectively amplify GC-rich ADAR-edited RNAs. *Nucleic Acids Res* 36:e72
74. Cuevas JM, Combe M, Torres-Puente M, Garijo R, Guix S, Buesa J, Rodríguez-Díaz J, Sanjuán R (2016) Human norovirus hyper-mutation revealed by ultra-deep sequencing. *Infect Genet Evol* 41:233–239
75. Chen R, Le RE, Kearney JA, Mansky LM, Benichou S (2004) Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. *J Biol Chem* 279:28419–28425
76. Mansky LM, Preveral S, Selig L, Benarous R, Benichou S (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 in vivo mutation rate. *J Virol* 74:7039–7047
77. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B (2004) Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. *J Biol Chem* 279:51545–51553
78. Holtz CM, Mansky LM (2013) Variation of HIV-1 mutation spectra among cell types. *J Virol* 87:5296–5299
79. Sardanyés J, Solé RV, Elena SF (2009) Replication mode and landscape topology differentially affect RNA virus mutational load and robustness. *J Virol* 83:12579–12589
80. Sardanyés J, Elena SF (2011) Quasispecies spatial models for RNA viruses with different replication modes and infection strategies. *PLoS One* 6:e24884
81. Thébaud G, Chadoeuf J, Morelli MJ, McCauley JW, Haydon DT (2010) The relationship between mutation frequency and replication strategy in positive-sense single-stranded RNA viruses. *Proc Biol Sci* 277:809–817
82. Chao L, Rang CU, Wong LE (2002) Distribution of spontaneous mutants and inferences about the replication mode of the RNA bacteriophage ϕ 6. *J Virol* 76:3276–3281
83. Garcia-Villada L, Drake JW (2012) The three faces of riboviral spontaneous mutation: spectrum, mode of genome replication, and mutation rate. *PLoS Genet* 8:e1002832
84. Martínez F, Sardanyés J, Elena SF, Daròs JA (2011) Dynamics of a plant RNA virus intracellular accumulation: stamping machine vs. geometric replication. *Genetics* 188:637–646
85. Schulte MB, Draghi JA, Plotkin JB, Andino R (2015) Experimentally guided models reveal replication principles that shape the mutation distribution of RNA viruses. *Elife* 4. doi:10.7554/eLife.03753
86. Combe M, Garijo R, Geller R, Cuevas JM, Sanjuán R (2015) Single-cell analysis of RNA virus infection identifies multiple genetically diverse viral genomes within single infectious units. *Cell Host Microbe* 18:424–432
87. Gillam S, Astell CR, Jahnke P, Hutchison CA III, Smith M (1984) Construction and properties of a ribosome-binding site mutation in gene E of ϕ X174 bacteriophage. *J Virol* 52:892–896
88. Hutchison CA III, Sinsheimer RL (1966) The process of infection with bacteriophage ϕ X174. X. Mutations in a ϕ X lysis gene. *J Mol Biol* 18:429–447

89. Bull JJ, Pfennig DW, Wang IN (2004) Genetic details, optimization and phage life histories. *Trends Ecol Evol* 19:76–82
90. Chantranupong L, Heineman RH (2012) A common, non-optimal phenotypic endpoint in experimental adaptations of bacteriophage lysis time. *BMC Evol Biol* 12:37
91. Heineman RH, Bull JJ (2007) Testing optimality with experimental evolution: lysis time in a bacteriophage. *Evolution* 61:1695–1709
92. Domingo-Calap P, Pereira-Gómez M, Sanjuán R (2012) Nucleoside analogue mutagenesis of a single-stranded DNA virus: evolution and resistance. *J Virol* 86:9640–9646
93. Pereira-Gómez M, Sanjuán R (2014) Delayed lysis confers resistance to the nucleoside analogue 5-fluorouracil and alleviates mutation accumulation in the single-stranded DNA bacteriophage ϕ X174. *J Virol* 88:5042–5049
94. Kunkel TA (1985) The mutational specificity of DNA polymerase-beta during in vitro DNA synthesis. Production of frameshift, base substitution, and deletion mutations. *J Biol Chem* 260:5787–5796
95. Yamanaka R, Termini J (2007) Nucleotide sequence context influences HIV replication fidelity by modulating reverse transcriptase binding and product release. *Biosci Trends* 1:52–61
96. Pathak VK, Temin HM (1992) 5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate. *J Virol* 66:3093–3100
97. Galetto R, Moumen A, Giacomoni V, Veron M, Charneau P, Negroni M (2004) The structure of HIV-1 genomic RNA in the gp120 gene determines a recombination hot spot in vivo. *J Biol Chem* 279:36625–36632
98. Simon-Loriere E, Galetto R, Hamoudi M, Archer J, Lefevre P, Martin DP, Robertson DL, Negroni M (2009) Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus. *PLoS Pathog* 5:e1000418
99. Geller R, Domingo-Calap P, Cuevas JM, Rossolillo P, Negroni M, Sanjuán R (2015) The external domains of the HIV-1 envelope are a mutational cold spot. *Nat Commun* 6:8571
100. Rawson JM, Landman SR, Reilly CS, Bonnac L, Patterson SE, Manky LM (2015) Lack of mutational hotspots during decitabine-mediated HIV-1 mutagenesis. *Antimicrob Agents Chemother* 59:6834–6843
101. Armitage AE, Katzourakis A, de Oliveira T, Welch JJ, Belshaw R, Bishop KN, Kramer B, McMichael AJ, Rambaut A, Iversen AK (2008) Conserved footprints of APOBEC3G on hypermutated human immunodeficiency virus type 1 and human endogenous retrovirus HERV-K(HML2) sequences. *J Virol* 82:8743–8761
102. Kijak GH, Janini LM, Tovanabutra S, Sanders-Buell E, Arroyo MA, Robb ML, Michael NL, Bix DL, McCutchan FE (2008) Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. *Virology* 376:101–111
103. Watts JM, Dang KK, Gorelick RJ, Leonard CW, Bess JW Jr, Swanstrom R, Burch CL, Weeks KM (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. *Nature* 460:711–716
104. Giguère T, Adkar-Purushothama CR, Perreault JP (2014) Comprehensive secondary structure elucidation of four genera of the family *Pospiviroidae*. *PLoS One* 9:e98655
105. Geller R, Estrada U, Peris JB, Andreu I, Bou J-V, Garijo R, Cuevas JM, Sabariego R, Mas A, Sanjuán R (2016) Highly heterogeneous mutation rates in the hepatitis C virus genome. *Nat Microbiol* 1:16045
106. Kwong PD, Mascola JR, Nabel GJ (2013) Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. *Nat Rev Immunol* 13:693–701
107. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, Zeisel MB, Baumert TF, Keck ZY, Fong SK, Pecheur EI, Pietschmann T (2010) Hepatitis C virus hyper-variable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. *J Virol* 84:5751–5763
108. Elde NC, Child SJ, Eickbush MT, Kitzman JO, Rogers KS, Shendure J, Geballe AP, Malik HS (2012) Poxviruses deploy genomic accordions to adapt rapidly against host antiviral defenses. *Cell* 150:831–841
109. Bikard D, Marraffini LA (2012) Innate and adaptive immunity in bacteria: mechanisms of programmed genetic variation to fight bacteriophages. *Curr Opin Immunol* 24:15–20
110. Guo H, Arambula D, Ghosh P, Miller JF (2014) Diversity-generating retroelements in phage and bacterial genomes. *Microbiol Spectr* 2:10–2014
111. Liu M, Deora R, Doulatov SR, Gingery M, Eiserling FA, Preston A, Maskell DJ, Simons RW, Cotter PA, Parkhill J, Miller JF (2002) Reverse transcriptase-mediated tropism switching in *Bordetella* bacteriophage. *Science* 295:2091–2094
112. Medhekar B, Miller JF (2007) Diversity-generating retroelements. *Curr Opin Microbiol* 10:388–395
113. Minot S, Grunberg S, Wu GD, Lewis JD, Bushman FD (2012) Hypervariable loci in the human gut virome. *Proc Natl Acad Sci USA* 109:3962–3966
114. Arambula D, Wong W, Medhekar BA, Guo H, Gingery M, Czornyj E, Liu M, Dey S, Ghosh P, Miller JF (2013) Surface display of a massively variable lipoprotein by a *Legionella* diversity-generating retroelement. *Proc Natl Acad Sci USA* 110:8212–8217
115. Doulatov S, Hodes A, Dai L, Mandhana N, Liu M, Deora R, Simons RW, Zimmerly S, Miller JF (2004) Tropism switching in *Bordetella* bacteriophage defines a family of diversity-generating retroelements. *Nature* 431:476–481
116. Paul BG, Bagby SC, Czornyj E, Arambula D, Handa S, Sczyrba A, Ghosh P, Miller JF, Valentine DL (2015) Targeted diversity generation by intraterrestrial archaea and archaeal viruses. *Nat Commun* 6:6585
117. Baroudy BM, Moss B (1982) Sequence homologies of diverse length tandem repetitions near ends of vaccinia virus genome suggest unequal crossing over. *Nucleic Acids Res* 10:5673–5679
118. Moss B, Winters E, Cooper N (1981) Instability and reiteration of DNA sequences within the vaccinia virus genome. *Proc Natl Acad Sci USA* 78:1614–1618
119. Munir M, Berg M (2013) The multiple faces of protein kinase R in antiviral defense. *Virulence* 4:85–89
120. Elde NC, Child SJ, Geballe AP, Malik HS (2009) Protein kinase R reveals an evolutionary model for defeating viral mimicry. *Nature* 457:485–489
121. Rothenburg S, Seo EJ, Gibbs JS, Dever TE, Dittmar K (2009) Rapid evolution of protein kinase PKR alters sensitivity to viral inhibitors. *Nat Struct Mol Biol* 16:63–70
122. Kerr PJ, Hone J, Perrin L, French N, Williams CK (2010) Molecular and serological analysis of the epidemiology of myxoma virus in rabbits. *Vet Microbiol* 143:167–178
123. Pérez-Losada M, Arenas M, Galán JC, Palero F, González-Candelas F (2015) Recombination in viruses: mechanisms, methods of study, and evolutionary consequences. *Infect Genet Evol* 30:296–307
124. Tromas N, Zwart MP, Poulain M, Elena SF (2014) Estimation of the in vivo recombination rate for a plant RNA virus. *J Gen Virol* 95:724–732
125. Gerrish PJ, Lenski RE (1998) The fate of competing beneficial mutations in an asexual population. *Genetica* 102–103:127–144

126. Xiao Y, Rouzine IM, Bianco S, Acevedo A, Goldstein EF, Farkov M, Brodsky L, Andino R (2016) RNA recombination enhances adaptability and is required for virus spread and virulence. *Cell Host Microbe* 19:493–503
127. Poirier EZ, Mounce BC, Rozen-Gagnon K, Hooikaas PJ, Stapleford KA, Moratorio G, Vignuzzi M (2015) Low-fidelity polymerases of alphaviruses recombine at higher rates to over-produce defective interfering particles. *J Virol* 90:2446–2454
128. Malpica JM, Fraile A, Moreno I, Obies CI, Drake JW, García-Arenal F (2002) The rate and character of spontaneous mutation in an RNA virus. *Genetics* 162:1505–1511
129. Wang W, Lee WM, Mosser AG, Rueckert RR (1998) WIN 52035-dependent human rhinovirus 16: assembly deficiency caused by mutations near the canyon surface. *J Virol* 72:1210–1218
130. Heinz BA, Rueckert RR, Shepard DA, Dutko FJ, McKinlay MA, Fancher M, Rossmann MG, Badger J, Smith TJ (1989) Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. *J Virol* 63:2476–2485
131. de la Torre JC, Giachetti C, Semler BL, Holland JJ (1992) High frequency of single-base transitions and extreme frequency of precise multiple-base reversion mutations in poliovirus. *Proc Natl Acad Sci USA* 89:2531–2535
132. Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. *Proc Natl Acad Sci USA* 96:13910–13913
133. de la Torre JC, Wimmer E, Holland JJ (1990) Very high frequency of reversion to guanidine resistance in clonal pools of guanidine-dependent type 1 poliovirus. *J Virol* 64:664–671
134. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R (2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. *Nature* 439:344–348
135. Sanjuán R, Agudelo-Romero P, Elena SF (2009) Upper-limit mutation rate estimation for a plant RNA virus. *Biol Lett* 5:394–396
136. Tromas N, Elena SF (2010) The rate and spectrum of spontaneous mutations in a plant RNA virus. *Genetics* 185:983–989
137. Cuevas JM, González-Candelas F, Moya A, Sanjuán R (2009) The effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. *J Virol* 83:5760–5764
138. Ribeiro RM, Li H, Wang S, Stoddard MB, Learn GH, Korber BT, Bhattacharya T, Guedj J, Parrish EH, Hahn BH, Shaw GM, Perelson AS (2012) Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. *PLoS Pathog* 8:e1002881
139. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR (2007) High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. *J Virol* 81:12135–12144
140. Holland JJ, de la Torre JC, Steinhauer DA, Clarke DK, Duarte EA, Domingo E (1989) Virus mutation frequencies can be greatly underestimated by monoclonal antibody neutralization of virions. *J Virol* 63:5030–5036
141. Drake JW (1993) Rates of spontaneous mutation among RNA viruses. *Proc Natl Acad Sci USA* 90:4171–4175
142. Furió V, Moya A, Sanjuán R (2005) The cost of replication fidelity in an RNA virus. *Proc Natl Acad Sci USA* 102:10233–10237
143. Combe M, Sanjuán R (2014) Variation in RNA virus mutation rates across host cells. *PLoS Pathog* 10:e1003855
144. Parvin JD, Moscona A, Pan WT, Leider JM, Palese P (1986) Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. *J Virol* 59:377–383
145. Nobusawa E, Sato K (2006) Comparison of the mutation rates of human influenza A and B viruses. *J Virol* 80:3675–3678
146. Stech J, Xiong X, Scholtissek C, Webster RG (1999) Independence of evolutionary and mutational rates after transmission of avian influenza viruses to swine. *J Virol* 73:1878–1884
147. Wong KK, Bull RA, Rockman S, Scott G, Stelzer-Braid S, Rawlinson W (2011) Correlation of polymerase replication fidelity with genetic evolution of influenza A/Fujian/411/02(H3N2) viruses. *J Med Virol* 83:510–516
148. Zhang X, Rennick LJ, Duprex WP, Rima BK (2013) Determination of spontaneous mutation frequencies in measles virus under nonselective conditions. *J Virol* 87:2686–2692
149. Schrag SJ, Rota PA, Bellini WJ (1999) Spontaneous mutation rate of measles virus: direct estimation based on mutations conferring monoclonal antibody resistance. *J Virol* 73:51–54
150. Pult I, Abbott N, Zhang YY, Summers J (2001) Frequency of spontaneous mutations in an avian hepdnavirus infection. *J Virol* 75:9623–9632
151. Pathak VK, Temin HM (1990) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. *Proc Natl Acad Sci USA* 87:6019–6023
152. Dougherty JP, Temin HM (1988) Determination of the rate of base-pair substitution and insertion mutations in retrovirus replication. *J Virol* 62:2817–2822
153. Varela-Echavarría A, Garvey N, Preston BD, Dougherty JP (1992) Comparison of Moloney murine leukemia virus mutation rate with the fidelity of its reverse transcriptase in vitro. *J Biol Chem* 267:24681–24688
154. Monk RJ, Malik FG, Stokesberry D, Evans LH (1992) Direct determination of the point mutation rate of a murine retrovirus. *J Virol* 66:3683–3689
155. Parthasarathi S, Varela-Echavarría A, Ron Y, Preston BD, Dougherty JP (1995) Genetic rearrangements occurring during a single cycle of murine leukemia virus vector replication: characterization and implications. *J Virol* 69:7991–8000
156. Drake JW, Charlesworth B, Charlesworth D, Crow JF (1998) Rates of spontaneous mutation. *Genetics* 148:1667–1686
157. Mansky LM, Temin HM (1994) Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus. *J Virol* 68:494–499
158. Mansky LM (2000) In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy. *J Virol* 74:9525–9531
159. Mansky LM, Temin HM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. *J Virol* 69:5087–5094
160. Mansky LM, Bernard LC (2000) 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1. *J Virol* 74:9532–9539
161. Gao F, Chen Y, Levy DN, Conway JA, Kepler TB, Hui H (2004) Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. *J Virol* 78:2426–2433
162. Huang KJ, Wooley DP (2005) A new cell-based assay for measuring the forward mutation rate of HIV-1. *J Virol Methods* 124:95–104
163. Abram ME, Ferris AL, Shao W, Alvord WG, Hughes SH (2010) Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. *J Virol* 84:9864–9878
164. Gartner K, Wiktorowicz T, Park J, Mergia A, Rethwilm A, Scheller C (2009) Accuracy estimation of foamy virus genome copying. *Retrovirology* 6:32
165. Leider JM, Palese P, Smith FI (1988) Determination of the mutation rate of a retrovirus. *J Virol* 62:3084–3091

166. Raney JL, DeLongchamp RR, Valentine CR (2004) Spontaneous mutant frequency and mutation spectrum for gene A of ϕ X174 grown in *E. coli*. *Environ Mol Mutagen* 44:119–127
167. Drake JW (1991) A constant rate of spontaneous mutation in DNA-based microbes. *Proc Natl Acad Sci USA* 88:7160–7164
168. Dove WF (1968) The genetic of the lambdoid phages. *Annu Rev Genet* 2:305–340
169. Lu Q, Hwang YT, Hwang CB (2002) Mutation spectra of herpes simplex virus type 1 thymidine kinase mutants. *J Virol* 76:5822–5828
170. Drake JW, Hwang CB (2005) On the mutation rate of herpes simplex virus type 1. *Genetics* 170:969–970
171. Luria SE (1951) The frequency distribution of spontaneous bacteriophage mutants as evidence for the exponential rate of phage reproduction. *Cold Spring Harb Symp Quant Biol* 16:463–470